{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 
| image = 
| width =

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Subcutaneous injection]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 863288-34-0
| CAS_supplemental = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 56841945
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 44750434

<!--Chemical data-->
| C=152 | H=252 | N=44 | O=42
| molecular_weight = 3367.89688 g/mol
| smiles = CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N
| StdInChI = 1S/C152H252N44O42/c1-22-79(15)118(194-125(214)84(20)171-135(224)107(68-115(206)207)181-124(213)81(17)169-126(215)91(155)65-87-41-45-89(201)46-42-87)147(236)189-106(66-86-34-25-24-26-35-86)141(230)196-120(85(21)200)149(238)180-99(51-54-114(158)205)132(221)190-111(72-199)145(234)185-105(67-88-43-47-90(202)48-44-88)140(229)178-96(40-33-59-168-152(164)165)128(217)177-94(37-28-30-56-154)133(222)193-117(78(13)14)146(235)187-100(60-73(3)4)134(223)170-82(18)123(212)175-97(49-52-112(156)203)130(219)183-103(63-76(9)10)138(227)191-109(70-197)143(232)172-83(19)122(211)174-95(39-32-58-167-151(162)163)127(216)176-93(36-27-29-55-153)129(218)182-102(62-75(7)8)137(226)184-101(61-74(5)6)136(225)179-98(50-53-113(157)204)131(220)186-108(69-116(208)209)142(231)195-119(80(16)23-2)148(237)188-104(64-77(11)12)139(228)192-110(71-198)144(233)173-92(121(159)210)38-31-57-166-150(160)161/h24-26,34-35,41-48,73-85,91-111,117-120,197-202H,22-23,27-33,36-40,49-72,153-155H2,1-21H3,(H2,156,203)(H2,157,204)(H2,158,205)(H2,159,210)(H,169,215)(H,170,223)(H,171,224)(H,172,232)(H,173,233)(H,174,211)(H,175,212)(H,176,216)(H,177,217)(H,178,229)(H,179,225)(H,180,238)(H,181,213)(H,182,218)(H,183,219)(H,184,226)(H,185,234)(H,186,220)(H,187,235)(H,188,237)(H,189,236)(H,190,221)(H,191,227)(H,192,228)(H,193,222)(H,194,214)(H,195,231)(H,196,230)(H,206,207)(H,208,209)(H4,160,161,166)(H4,162,163,167)(H4,164,165,168)/t79-,80-,81+,82-,83-,84-,85+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,117-,118-,119-,120-/m0/s1
| StdInChIKey = XOZMWINMZMMOBR-HRDSVTNWSA-N
| synonyms = 
}}

'''CJC-1295''', also known as '''DAC:GRF''' (short for '''drug affinity complex:growth hormone-releasing factor'''), is a [[Organic compound#Synthetic compounds|synthetic]] [[structural analog|analogue]] of [[growth hormone-releasing hormone]] (GHRH) (also known as ''growth hormone-releasing factor'' (''GRF'')) and a [[growth hormone secretagogue]] (GHS) which was developed by [[ConjuChem Biotechnologies]].<ref name="JettéLéger2005">{{cite journal|last1=Jetté|first1=Lucie|last2=Léger|first2=Roger|last3=Thibaudeau|first3=Karen|last4=Benquet|first4=Corinne|last5=Robitaille|first5=Martin|last6=Pellerin|first6=Isabelle|last7=Paradis|first7=Véronique|last8=van Wyk|first8=Pieter|last9=Pham|first9=Khan|last10=Bridon|first10=Dominique P.|title=Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog|journal=Endocrinology|volume=146|issue=7|year=2005|pages=3052–3058|issn=0013-7227|doi=10.1210/en.2004-1286|url=http://www.researchgate.net/profile/Dominique_Bridon/publication/228484039_hGRF1-29-Albumin_Bioconjugates_Activate_the_GRF_Receptor_on_the_Anterior_Pituitary_in_Rats_Identification_of_CJC-1295_as_a_Long_Lasting_GRF_Analog/links/09e41513e01126aeaf000000.pdf|pmid=15817669}}</ref><ref name="AlbaFintini2006">{{cite journal|last1=Alba|first1=M.|last2=Fintini|first2=D.|last3=Sagazio|first3=A.|last4=Lawrence|first4=B.|last5=Castaigne|first5=J.-P.|last6=Frohman|first6=L. A.|last7=Salvatori|first7=R.|title=Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse|journal=AJP: Endocrinology and Metabolism|volume=291|issue=6|year=2006|pages=E1290–E1294|issn=0193-1849|doi=10.1152/ajpendo.00201.2006}}</ref><ref name="TeichmanNeale2006">{{cite journal|last1=Teichman|first1=Sam L.|last2=Neale|first2=Ann|last3=Lawrence|first3=Betty|last4=Gagnon|first4=Catherine|last5=Castaigne|first5=Jean-Paul|last6=Frohman|first6=Lawrence A.|title=Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults|journal=The Journal of Clinical Endocrinology & Metabolism|volume=91|issue=3|year=2006|pages=799–805|issn=0021-972X|doi=10.1210/jc.2005-1536|pmid=16352683}}</ref> It is a modified form of [[sermorelin|GHRH (1-29)]] with improved [[pharmacokinetics]], especially in regard to [[half-life]].<ref name="JettéLéger2005" /><ref name="AlbaFintini2006" /><ref name="TeichmanNeale2006" /><ref name="Thorner2008">{{cite journal|last1=Thorner|first1=Michael O.|title=The Discovery of Growth Hormone-Releasing Hormone1: An Update|journal=Journal of Neuroendocrinology|volume=20|issue=6|year=2008|pages=653–654|issn=0953-8194|doi=10.1111/j.1365-2826.2008.01740.x}}</ref>

CJC-1295 markedly increases [[Blood plasma|plasma]] [[growth hormone]] (GH) and [[insulin-like growth factor 1]] (IGF-1) levels in both animals and humans.<ref name="JettéLéger2005" /><ref name="AlbaFintini2006" /><ref name="TeichmanNeale2006" /><ref name="IonescuFrohman2006">{{cite journal|last1=Ionescu|first1=Madalina|last2=Frohman|first2=Lawrence A.|title=Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog|journal=The Journal of Clinical Endocrinology & Metabolism|volume=91|issue=12|year=2006|pages=4792–4797|issn=0021-972X|doi=10.1210/jc.2006-1702}}</ref> With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 1.5- to 3-fold for 9 to 11 days.<ref name="TeichmanNeale2006" /> The drug has an estimated [[half-life]] of about 6 to 8 days in humans.<ref name="TeichmanNeale2006" /> With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.<ref name="TeichmanNeale2006" />

CJC-1295 has been shown to extend the half-life and bioavailability of [[growth-hormone-releasing hormone]] 1-29 and stimulate [[insulin-like growth factor 1]] secretion. It increases the half-life of acting agents by [[bioconjugation]].<ref>{{cite web|title=Current Research Findings Regarding CJC-1295|url=http://neobiolab.com/research/current-research-findings-regarding-cjc-1295|publisher=Neo Scientific|accessdate=3 August 2015|quote=The reason why CJC1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new in nature, is defined by its ability to take a reactive group and bond it to a peptide (Aslam and Dent). This attachment causes a reaction with a nucleophilic unit; a typically partially molecule that is found within the bloodstream of an animal test subject. This reaction in turn causes a more stable bond to occur.  This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water.  This affinity prohibits natural degradation, which in turn increases the peptide’s half-life (Hermanson). Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced (Gonzalez, US Peptide Articles).}}</ref>

CJC-1295 was under investigation for the treatment of [[lipodystrophy]] and [[growth hormone deficiency]] and reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s but was discontinued upon the death of one of the trial subjects.<ref name="Andersen HartvigBjerre Holm2014">{{cite journal|last1=Andersen Hartvig|first1=Rune|last2=Bjerre Holm|first2=Niels|last3=Weihe Dalsgaard|first3=Petur|last4=Ask Reitzel|first4=Lotte|last5=Breum Müller|first5=Irene|last6=Linnet|first6=Kristian|title=Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013|journal=Scandinavian Journal of Forensic Science|volume=20|issue=2|year=2014|issn=2353-0707|doi=10.2478/sjfs-2014-0003}}</ref><ref name="ConjuChem2006">{{cite web|url=http://www.natap.org/2006/newsUpdates/081106_02.htm|author=ConjuChem|title=Patient Died in Lipodystrophy Drug Study| date=August 2006 }}</ref> The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic [[coronary artery disease]] with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295.<ref name="ConjuChem2006" /> In any case, research was terminated nonetheless as a precaution.<ref name="ConjuChem2006" /> CJC-1295 has found [[black market]] use for [[bodybuilding]] purposes, with this, in some countries such as the [[Netherlands]], being an [[illicit use]].<ref name="Andersen HartvigBjerre Holm2014" /><ref name="HenningePepaj2010">{{cite journal|last1=Henninge|first1=John|last2=Pepaj|first2=Milaim|last3=Hullstein|first3=Ingunn|last4=Hemmersbach|first4=Peter|title=Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation|journal=Drug Testing and Analysis|volume=2|issue=11-12|year=2010|pages=647–650|issn=1942-7603|doi=10.1002/dta.233}}</ref>

==See also==
* [[Modified GRF (1-29)]]
* [[Sermorelin]]
* [[Tesamorelin]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800018006 CJC-1295 - AdisInsight]


{{GH/IGF-1 axis signaling modulators}}

[[Category:Growth hormone-releasing hormone receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Peptides]]
[[Category:World Anti-Doping Agency prohibited substances]]
[[Category:Abandoned drugs]]